Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once — Daily, N — Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
For best results when printing this announcement, please click on link below: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026 virtually and at the Walter E. Washington Convention Center in Washington, DC. Details of the presentation are as follows: Poster Title: Zelicapavir Decreases Time to Complete RSV Symptom Resolution, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo (PBO)-Controlled Phase 2 Trial of High-Risk Adults Poster Session: Novel Agents Poster Number: 3 Date: Thursday October 22, 2026 Time: 12:15 PM — 1:30 PM ET Location: Poster Hall B-C Presenter: Christopher E. Harris, M.D. The poster will be available to vi
For best results when printing this announcement, please click on link below: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 Enanta Pharmaceuticals, Inc.
(NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026 virtually and at the Walter E. Washington Convention Center in Washington, DC.
Details of the presentation are as follows: Poster Title: Zelicapavir Decreases Time to Complete RSV Symptom Resolution, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo (PBO)-Controlled Phase 2 Trial of High-Risk Adults Poster Session: Novel Agents Poster Number: 3 Date: Thursday October 22, 2026 Time: 12:15 PM — 1:30 PM ET Location: Poster Hall B-C Presenter: Christopher E. D. The poster will be available to view on the conference platform during the conference and on the Company’s website here ( ). Further information about IDWeek™ 2026 can be found here About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition. ) (glecaprevir/pibrentasvir).
A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit for more information. com)